MODULATORS OF MAS-BOUND G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS Russian patent published in 2025 - IPC C07D215/40 C07D239/94 C07D401/12 C07D403/12 A61K31/517 A61P17/04 A61P29/00 A61P37/08 

FIELD: chemistry.

SUBSTANCE: disclosed are compounds having the structure (I):

or a pharmaceutically acceptable salt or isomer thereof, wherein R¹ is phenyl or 5-9 membered heterocyclyl containing 1-3 heteroatoms selected from N and O, wherein R¹ is optionally substituted with one or more R^q; each R^q is independently C_1-6 alkyl, phenyl, C₃ cycloalkyl, 5–6 membered heterocyclyl containing 1–3 heteroatoms selected from N and S, -OR, -C(O)OR, -C(O)R, -X, -CX₃, -CX₂H, -C(X)H₂, -CN, -N(R)₂, -N(R)C(O)R, -N(R)S(O)₂R, -S(O)₂R or -(CH₂)_nQ’, where Q' is X, -CX₃, -CX₂H, -CN; each R is independently H, C_1-6 alkyl, phenyl or 5-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S; R², R³, R⁴, R⁵ and R⁶ independently represent H, C_1-6 alkyl, X, -CX₃, -CX₂H or -CN; each R^x independently represents H; W is N; Z is or CR^z; R^z is H; each X is independently F, Cl, Br or I; and each n is independently equal to 1 or 2, as well as a pharmaceutical composition based thereon and a method of treating a MRGPR X2 dependent or MRGPR X2 ortholog dependent condition.

EFFECT: novel compounds which can be used to treat a MRGPR X2 dependent or MRGPR X2 ortholog are obtained.

24 cl, 8 tbl, 32 ex